In cases with concomitant IL-2 + 5-FU treatment, the incidence of CLS varied from 6.3% to 25.0%, resulting in 17.5% by overall estimation and 17.1% by meta-analysis. The gene discussed is IL2; the disease is capillary leak syndrome.